Patents by Inventor Steven W. Sutton

Steven W. Sutton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8299028
    Abstract: The chimeric polypeptide R3(B?23-27)R/I5 is described, which is a high-affinity antagonist for GPCR1 35 and GPCR1 42 over LGR7.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: October 30, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Chester Kuei, Changlu Liu, Cindy M. Pudiak, Jonathan Edward Shelton, Steven W. Sutton
  • Patent number: 7893197
    Abstract: Chimeric polypeptides of relaxin-3, prepropolypeptides thereof, polynucleotides encoding such polypeptides, and associated expression vectors and host cells are described. The polypeptides may be used to prepare receptor-ligand complexes with GPCR135 or GPCR142, which may be used in assay methods.
    Type: Grant
    Filed: August 25, 2005
    Date of Patent: February 22, 2011
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Pascal Bonaventure, Chester Kuei, Changlu Liu, Timothy W. Lovenberg, Steven W. Sutton
  • Publication number: 20100145007
    Abstract: The chimeric polypeptide R3(B?23-27)R/I5 is described, which is a high-affinity antagonist for GPCR1 35 and GPCR1 42 over LGR7.
    Type: Application
    Filed: January 23, 2008
    Publication date: June 10, 2010
    Inventors: Chester Kuei, Changlu Liu, Cindy M. Pudiak, Jonathan Shelton, Steven W. Sutton
  • Patent number: 7618786
    Abstract: The present invention provides a new method for identifying modulators of human orexin-2 receptor without utilizing recombinantly produced nucleic acid molecules encoding human orexin receptor protein. This method combines and utilizes known methods and cell lines selected for their natural expression of orexin-2 receptors to carry out the methods of the present invention. Exemplary methods of the present invention utilize PFSK-1 cells to produce non-recombinant human orexin-2 receptor protein.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: November 17, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Steven W. Sutton, Timothy W. Lovenberg
  • Patent number: 6951882
    Abstract: Urea-containing, substituted 4-phenyl-[1,3]-dioxanes, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, obesity or a sleep/wake disorder mediated by orexin-2 are described.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: October 4, 2005
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Nicholas I Carruthers, Todd K. Jones, Xiaobing Li, Timothy W. Lovenberg, Laura C. McAtee, Victor K. Phuong, Dale A. Rudolph, Steven W. Sutton
  • Publication number: 20040147593
    Abstract: Urea-containing, substituted 4-phenyl-[1,3]-dioxanes, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, obesity or a sleep/wake disorder mediated by orexin-2 are described.
    Type: Application
    Filed: December 12, 2003
    Publication date: July 29, 2004
    Inventors: Nicholas I. Carruthers, Todd K. Jones, Xiaobing Li, Timothy W. Lovenberg, Laura C. McAtee, Victor K. Phuong, Dale A. Rudolph, Steven W. Sutton
  • Patent number: 5330221
    Abstract: An auxiliary device attachable to a bicycle to aid in learning the stunt known as "popping wheelies" balance on the rear wheel of the bicycle, the device including a rearwardly extending support frame, a rear frame pivotally attached at one end to the support frame and pivotally attached at the other end to a member that is lengthwise adjustably attached to the support frame with a pair of wheels on an axle flexibly attached to the rear frame.
    Type: Grant
    Filed: January 15, 1993
    Date of Patent: July 19, 1994
    Inventor: Steven W. Sutton